Early Experiences With COVID-19 Testing in Transplantation.
Journal
Transplantation direct
ISSN: 2373-8731
Titre abrégé: Transplant Direct
Pays: United States
ID NLM: 101651609
Informations de publication
Date de publication:
Jul 2020
Jul 2020
Historique:
received:
06
05
2020
revised:
08
05
2020
accepted:
09
05
2020
entrez:
9
8
2020
pubmed:
9
8
2020
medline:
9
8
2020
Statut:
epublish
Résumé
The early effects of coronavirus disease 2019 (COVID-19) on transplantation are dramatic: >75% of kidney and liver programs are either suspended or operating under major restrictions. To resume transplantation, it is important to understand the prevalence of COVID-19 among transplant recipients, donors, and healthcare workers (HCWs) and its associated mortality. To investigate this, we studied severe acute respiratory syndrome coronavirus 2 diagnostic test results among patients with end-stage renal disease or kidney transplants from the Johns Hopkins Health System (n = 235), and screening test results from deceased donors from the Southwest Transplant Alliance Organ Procurement Organization (n = 27), and donors, candidates, and HCWs from the National Kidney Registry and Viracor-Eurofins (n = 253) between February 23 and April 15, 2020. We found low rates of COVID-19 among donors and HCWs (0%-1%) who were screened, higher rates of diagnostic tests among patients with end-stage renal disease or kidney transplant (17%-20%), and considerable mortality (7%-13%) among those who tested positive. These findings suggest the threat of COVID-19 for the transplant population is significant and ongoing data collection and reporting is critical to inform transplant practices during and after the pandemic.
Sections du résumé
BACKGROUND
BACKGROUND
The early effects of coronavirus disease 2019 (COVID-19) on transplantation are dramatic: >75% of kidney and liver programs are either suspended or operating under major restrictions. To resume transplantation, it is important to understand the prevalence of COVID-19 among transplant recipients, donors, and healthcare workers (HCWs) and its associated mortality.
METHODS
METHODS
To investigate this, we studied severe acute respiratory syndrome coronavirus 2 diagnostic test results among patients with end-stage renal disease or kidney transplants from the Johns Hopkins Health System (n = 235), and screening test results from deceased donors from the Southwest Transplant Alliance Organ Procurement Organization (n = 27), and donors, candidates, and HCWs from the National Kidney Registry and Viracor-Eurofins (n = 253) between February 23 and April 15, 2020.
RESULTS
RESULTS
We found low rates of COVID-19 among donors and HCWs (0%-1%) who were screened, higher rates of diagnostic tests among patients with end-stage renal disease or kidney transplant (17%-20%), and considerable mortality (7%-13%) among those who tested positive.
CONCLUSIONS
CONCLUSIONS
These findings suggest the threat of COVID-19 for the transplant population is significant and ongoing data collection and reporting is critical to inform transplant practices during and after the pandemic.
Identifiants
pubmed: 32766427
doi: 10.1097/TXD.0000000000001024
pmc: PMC7339314
doi:
Types de publication
Journal Article
Langues
eng
Pagination
e572Subventions
Organisme : NIAID NIH HHS
ID : T32 AI007291
Pays : United States
Organisme : NIDDK NIH HHS
ID : F32 DK117563
Pays : United States
Organisme : NIDDK NIH HHS
ID : K01 DK101677
Pays : United States
Organisme : NIDDK NIH HHS
ID : K23 DK115908
Pays : United States
Organisme : NIDDK NIH HHS
ID : T32 DK007713
Pays : United States
Organisme : NIDDK NIH HHS
ID : K24 DK101828
Pays : United States
Organisme : NHLBI NIH HHS
ID : T32 HL007055
Pays : United States
Organisme : NIDDK NIH HHS
ID : F32 DK113719
Pays : United States
Informations de copyright
Copyright © 2020 The Author(s). Transplantation Direct. Published by Wolters Kluwer Health, Inc.
Déclaration de conflit d'intérêts
The authors declare no conflicts of interest.
Références
JAMA Intern Med. 2020 Mar 13;:
pubmed: 32167524
J Am Soc Nephrol. 2020 Jun;31(6):1150-1156
pubmed: 32317402
Am J Transplant. 2020 Jul;20(7):1809-1818
pubmed: 32282982
JAMA. 2020 Feb 24;:
pubmed: 32091533
J Korean Med Sci. 2020 Mar 30;35(12):e137
pubmed: 32233163
Lancet. 2020 Feb 15;395(10223):497-506
pubmed: 31986264
Kidney Int. 2020 Jun;97(6):1083-1088
pubmed: 32354634
Lancet. 2020 Feb 15;395(10223):507-513
pubmed: 32007143
Clin Chim Acta. 2020 Aug;507:94-97
pubmed: 32315614
N Engl J Med. 2020 Jun 11;382(24):2302-2315
pubmed: 32289214
Am J Transplant. 2020 Jul;20(7):1907-1910
pubmed: 32277591
Emerg Infect Dis. 2020 Jun;26(6):1251-1256
pubmed: 32168464
J Clin Virol. 2020 Jun;127:104371
pubmed: 32315817
JAMA. 2020 Mar 23;:
pubmed: 32203977
N Engl J Med. 2020 Feb 20;382(8):727-733
pubmed: 31978945
Am J Transplant. 2020 Jul;20(7):1941-1943
pubmed: 32233067
Kidney Int. 2020 Jun;97(6):1076-1082
pubmed: 32354637
Lancet. 2020 Mar 28;395(10229):1054-1062
pubmed: 32171076
Am J Transplant. 2020 Jul;20(7):1859-1863
pubmed: 32181990
N Engl J Med. 2020 Mar 5;382(10):929-936
pubmed: 32004427
Transplantation. 2020 Apr 1;:
pubmed: 32243281
Elife. 2020 Feb 24;9:
pubmed: 32091395
Eur Respir J. 2020 May 14;55(5):
pubmed: 32217650
J Clin Med. 2020 Feb 21;9(2):
pubmed: 32098019
Lancet Infect Dis. 2020 Mar;20(3):292-293
pubmed: 32078809
Am J Transplant. 2020 Jul;20(7):1773-1779
pubmed: 32202064
Am J Transplant. 2020 Jul;20(7):1768-1772
pubmed: 32090448
J Clin Med. 2020 Feb 14;9(2):
pubmed: 32075152